Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.
Front Immunol. 2024 Aug 7;15:1444621. doi: 10.3389/fimmu.2024.1444621. eCollection 2024.
Simian immunodeficiency virus (SIV) vaccines based upon 68-1 Rhesus Cytomegalovirus (RhCMV) vectors show remarkable protection against pathogenic SIVmac239 challenge. Across multiple independent rhesus macaque (RM) challenge studies, nearly 60% of vaccinated RM show early, complete arrest of SIVmac239 replication after effective challenge, whereas the remainder show progressive infection similar to controls. Here, we performed viral sequencing to determine whether the failure to control viral replication in non-protected RMs is associated with the acquisition of viral escape mutations. While low level viral mutations accumulated in all animals by 28 days-post-challenge, which is after the establishment of viral control in protected animals, the dominant circulating virus in virtually all unprotected RMs was nearly identical to the challenge stock, and there was no difference in mutation patterns between this cohort and unvaccinated controls. These data definitively demonstrate that viral mutation does not explain lack of viral control in RMs not protected by RhCMV/SIV vaccination. We further demonstrate that during chronic infection RhCMV/SIV vaccinated RMs do not acquire escape mutation in epitopes targeted by RhCMV/SIV, but instead display mutation in canonical MHC-Ia epitopes similar to unvaccinated RMs. This suggests that after the initial failure of viral control, unconventional T cell responses induced by 68-1 RhCMV/SIV vaccination do not exert strong selective pressure on systemically replicating SIV.
猿猴免疫缺陷病毒(SIV)基于 68-1 恒河猴巨细胞病毒(RhCMV)载体的疫苗在预防致病性 SIVmac239 感染方面显示出显著的保护作用。在多个独立的恒河猴(RM)挑战研究中,近 60%的接种 RM 在有效接种后早期完全阻止了 SIVmac239 的复制,而其余的 RM 则表现出与对照相似的进行性感染。在这里,我们进行了病毒测序,以确定在未受保护的 RM 中未能控制病毒复制是否与获得病毒逃逸突变有关。虽然所有动物在接种后 28 天(即保护动物建立病毒控制后)都会积累低水平的病毒突变,但在几乎所有未受保护的 RM 中,主要循环病毒几乎与挑战株相同,并且在这一组和未接种对照之间,突变模式没有差异。这些数据明确表明,病毒突变不能解释 RhCMV/SIV 疫苗未保护的 RM 中病毒控制的失败。我们进一步表明,在慢性感染期间,RhCMV/SIV 接种的 RM 不会在 RhCMV/SIV 靶向的表位中获得逃逸突变,而是在与未接种 RM 相似的经典 MHC-Ia 表位中显示突变。这表明,在最初的病毒控制失败后,68-1 RhCMV/SIV 疫苗诱导的非常规 T 细胞反应不会对全身复制的 SIV 产生强烈的选择压力。